Zoledronic Acid Accord zoledronic acid 4mg/5mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

zoledronic acid accord zoledronic acid 4mg/5ml concentrated injection vial

accord healthcare pty ltd - zoledronic acid monohydrate, quantity: 4.264 mg (equivalent: zoledronic acid, qty 4 mg) - injection, concentrated - excipient ingredients: sodium citrate dihydrate; mannitol; water for injections - zoledronic acid accord is indicated:,for the prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone.,for treatment of tumour-induced hypercalcaemia.,as an adjunct to adjuvant treatment for women with early breast cancer who are in established menopause.

Carmustine Accord carmustine 100 mg powder for injection vial with diluent Australia - English - Department of Health (Therapeutic Goods Administration)

carmustine accord carmustine 100 mg powder for injection vial with diluent

accord healthcare pty ltd - carmustine, quantity: 100 mg - diluent, not applicable - excipient ingredients: ethanol absolute - carmustine accord is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following:,1. malignant glioma,2. multiple myeloma - in combination with prednisone.,3. hodgkin?s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.,4. non-hodgkin?s lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.

AZACITIDINE ACCORD azacitidine 100mg powder for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

azacitidine accord azacitidine 100mg powder for injection vial

accord healthcare pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - azacitidine accord is indicated for the treatment of patients with,? intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), ,? chronic myelomonocytic leukemia (cmmol (10-29 percent marrow blasts without myeloproliferative disorder)), ,? acute myeloid leukemia (aml) with 20-30 percent blasts and multi-lineage dysplasia, according to world health organisation classification (who), ,in whom allogenic stem cell transplantation is not indicated.

BUSULFAN ACCORD busulfan 60 mg/10 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

busulfan accord busulfan 60 mg/10 ml concentrated injection vial

accord healthcare pty ltd - busulfan, quantity: 60 mg - injection, concentrated - excipient ingredients: macrogol 400; dimethylacetamide - busulfan accord is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.

BORTEZOMIB ACCORD bortezomib 3.5 mg/1.4 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

bortezomib accord bortezomib 3.5 mg/1.4 ml solution for injection vial

accord healthcare pty ltd - bortezomib, quantity: 3.5 mg - injection, solution - excipient ingredients: mannitol; water for injections - bortezomib accord, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib accord, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib accord is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

BORTEZOMIB ACCORD bortezomib 2.5 mg/1 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

bortezomib accord bortezomib 2.5 mg/1 ml solution for injection vial

accord healthcare pty ltd - bortezomib, quantity: 2.5 mg - injection, solution - excipient ingredients: mannitol; water for injections - bortezomib accord, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib accord, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib accord is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

CISPLATIN ACCORD cisplatin 25 mg/25 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cisplatin accord cisplatin 25 mg/25 ml concentrated injection vial

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

CISPLATIN ACCORD cisplatin 100 mg/100 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cisplatin accord cisplatin 100 mg/100 ml concentrated injection vial

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

CISPLATIN ACCORD cisplatin 10 mg/10 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cisplatin accord cisplatin 10 mg/10 ml concentrated injection vial

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; water for injections; sodium hydroxide; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck

CISPLATIN ACCORD cisplatin 50 mg/50 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cisplatin accord cisplatin 50 mg/50 ml concentrated injection vial

accord healthcare pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; hydrochloric acid - cisplatin accord may be used as a monotherapy or in combination with other chemotherapeutic agents in the treatment of:,? metastatic non-seminomatous germ cell carcinoma,? advanced stage, refractory ovarian carcinoma,? advanced stage, refractory bladder carcinoma,? refractory squamous cell carcinoma of the head and neck